Related Experiment Video

Updated: Jun 21, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

[Rosuvastatin attenuates vascular endothelial adhesiveness in apolipoprotein E-deficient mice]

Wei Li1, Hai-ying Huang, Zhi-yong Wu

  • 1Department of Geriatrics, Hainan Provincial People's Hospital, Haikou 570311, China.

Zhonghua Xin Xue Guan Bing Za Zhi
|August 13, 2009
PubMed
Abstract

Insights

Rosuvastatin reduces inflammation in the blood vessel walls of mice lacking apolipoprotein E. This study shows rosuvastatin

Area of Science:

  • Pharmacology
  • Cardiovascular Biology
  • Inflammation Research

Context:

  • Atherogenesis is a complex inflammatory process.
  • Apolipoprotein E-deficient (ApoE-/-) mice are a standard model for studying atherosclerosis.
  • Understanding the vascular anti-inflammatory effects of statins is crucial for cardiovascular disease management.

Purpose:

  • To evaluate the anti-inflammatory impact of rosuvastatin on the blood vessel walls.
  • To determine rosuvastatin's effect on endothelial cell adhesion and inflammatory markers in ApoE-/- mice.

Summary:

  • ApoE-/- mice were treated with rosuvastatin (1, 5, or 20 mg/kg) or vehicle for 2 or 6 weeks.
  • Functional assays measured endothelial adhesiveness for monocytes.
  • Quantitative real-time PCR assessed vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemotactic protein-1 (MCP-1) expression.

Impact:

  • Rosuvastatin treatment significantly reduced monocyte adhesion to the endothelium.
  • The drug markedly decreased VCAM-1 and MCP-1 expression in the vessel wall.
  • These findings suggest rosuvastatin's anti-inflammatory actions contribute to mitigating atherogenesis in this model.

More Related Videos

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...